NCT06573138: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
- State
- Not started
- Phase
- Phase 2
- People
- 18 planned
- Started
- 1 Sep 2024
- Primary completion
- 1 Jul 2027
- Arms
- Chemofree
- Results
- None posted
- 27 Aug 2024: Trial registered
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.
Kind of treatment: Drug.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.